Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Date:4/21/2009

sion (abstract #3594) during the American Association for Cancer Research's 100th Annual Meeting 2009 at the Colorado Convention Center in Denver.

Phase 1 Study Design and Results

Poniard's randomized, open-label, dose-ranging Phase 1 study was conducted at clinical sites in the United States. The trial compared the bioavailability, pharmacokinetics, pharmacodynamics and safety of picoplatin administered orally with picoplatin administered intravenously to patients with advanced solid tumor malignancies. Bioavailability refers to the fraction of an administered dose of an unchanged drug that reaches systemic circulation. In the first part of this two-part trial, patients with advanced solid tumor malignancies were randomized to a single dose of either intravenous (120 mg/m squared) or oral picoplatin (200 mg, 300 mg or 400 mg). Four weeks later, they received a second single picoplatin dose administered via the other route. In the second part of the trial, patients received only a single oral dose of picoplatin (including doses of 50 mg and 100 mg).

Final results showed that oral picoplatin achieved oral bioavailability of nearly 100 percent at doses of 50 mg and 100 mg. No meaningful differences in pharmacokinetics were observed between the two formulations. All doses of the oral dose were well tolerated. No serious adverse events related to treatment were noted following administration of the oral dose.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that it has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other pl
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
5. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
6. Poniard Pharmaceuticals Receives Going Concern Qualification
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
9. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... 2014) The cause of neuronal death in Parkinson,s ... that neurons may be mistaken for foreign invaders and ... the way autoimmune diseases like type I diabetes, celiac ... study was published April 16, 2014, in Nature ... controversial, idea in Parkinson,s disease; but if true, it ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
(Date:4/17/2014)... Meaningful long-term survival is possible for selected ... when treated with cytoreductive surgery with Hyperthermic IntraPeritoneal ... by physicians at Wake Forest Baptist Medical Center. ... single-center experience with cytoreductive surgery and HIPEC, said ... of 20 years, worth of patient data shows ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... (MTX) is commonly used to treat rheumatoid arthritis (RA) ... the disease. Despite its widespread use, the understanding of ... joint damage occurs early in the course of RA ... for stable levels of MTX to be reached could ...
... Drug Co-Pays, HOUSTON, Nov. 4 US Oncology ... specialty pharmacy, has,exceeded the $10 million mark in assisting ... of Care Advantage in August 2006., "It was ... to,increase patient access to oral chemotherapies by easing the ...
... defined cell culture media components will feature its productivity maximizing product ... ... CO (PRWEB) November 4, 2008 -- InVitria,s Cellastim (recombinant albumin), which ... will be featured at the 2nd International Cell Engineering Meeting hosted ...
... insecurity, , , TUESDAY, Nov. 4 (HealthDay News) -- Children who ... and undernourished, a new study finds. , The same is ... the impact the most, said study author Dr. Michael Weitzman, ... , "We know that there are long-term consequences of food ...
... 4 Vericept, the leading provider,of data ... is,proud to announce the achievement of a ... in the healthcare industry have selected,Vericept,s DLP ... with,HIPAA, as well as safeguard patient data ...
... Nov. 4 Jennerex, Inc. (San Francisco, CA,and Ottawa, ... Kirn, M.D., President and Chief Executive Officer,will present an ... & Renshaw,Healthcare Conference in New York on November 11, ... at the Palace Hotel, New York., A webcast ...
Cached Medicine News:Health News:Wide variability in rheumatoid arthritis drug suggests alternative dosing should be considered 2Health News:Wide variability in rheumatoid arthritis drug suggests alternative dosing should be considered 3Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 3Health News:InVitria to Present at WilBio's International Cell Engineering Meeting 2Health News:Smokers' Homes More Likely to House Hungry Kids 2Health News:Smokers' Homes More Likely to House Hungry Kids 3Health News:Vericept Announces 100 Customers in Healthcare Industry for Sensitive Data Protection 2Health News:Jennerex To Present at Rodman & Renshaw 10th Annual Healthcare Conference 2
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... 11, 2011 Tonight,s "Dan Rather Reports" examines ... of antibiotics. Every year, more than 90,000 Americans ... antibiotic-resistant infections, caused directly by the overuse of ... $35 billion a year.  In tonight,s program, Dan ...
... 2011 WebMD Health Corp. (Nasdaq: WBMD ) ... million aggregate principal amount of 2.50% Convertible Notes due 2018 ... the exercise in full of the initial purchaser,s over-allotment option). ... to Rule 144A under the Securities Act of 1933.   ...
Cached Medicine Technology:Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 2Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 3Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 4WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2
... True/Flex Upper Extremity Intramedullary Rod System offers ... to conventional methods of rodding and plating. ... at the fracture site and enhanced healing4 ... to be easily inserted into the canal. ...
Interphlex Flexible Stablization Rods offer correction of Hammer Toes with a High level of Flexibility while maintaining correct toe length and shape....
The True/Fix Compression Hip Screw System offers a wide variety of plate and screw sizes available....
... Simple, cost-effective microfiltration for your transfusion ... also brings you an easy and ... of microfiltration for a variety of ... postoperative applications, autologous or homologous transfusions, ...
Medicine Products: